The Alzheimer's Disease Tau Platform Clinical Trial — ADAM L. BOXER (UNIVERSITY OF CALIFORNIA, SAN FRANCISCO)
PROJECT SUMMARY / ABSTRACT Tau protein is an attractive AD therapeutic target because the amount and anatomical distribution of insoluble tau at autopsy is strongly correlated with the symptoms and se
| Project title | The Alzheimer's Disease Tau Platform Clinical Trial |
|---|---|
| Project number | 5R01AG078457-02 |
| PI name | ADAM L. BOXER |
| Institution | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO |
| Funding mechanism | R01 |
| Agency | NIA |
| Award amount | $29.81M |
| Fiscal year | 2024 |
| Project start | 2023-09-21T00:00:00 |
| Project end | 2029-08-31T00:00:00 |
| Abstract | PROJECT SUMMARY / ABSTRACT Tau protein is an attractive AD therapeutic target because the amount and anatomical distribution of insoluble tau at autopsy is strongly correlated with the symptoms and se |
| Key terms | <AD dementia><AD pathology><Acceleration><Address><Alzheimer Type Dementia><Alzheimer beta-Protein>< |
$799/mo
Try GrantRadar →